Please login to the form below

Not currently logged in
Email:
Password:

NOR-SWITCH

This page shows the latest NOR-SWITCH news and features for those working in and with pharma, biotech and healthcare.

Standing out in a crowd

Standing out in a crowd

explained. Switching. Once products reached the market Celltrion observed further challenges when it came to persuading physicians to switch patients from originator biologics to their biosimilar equivalents. ... This is despite work to study the effects

Latest news

  • Facing the new wave of biosimilars Facing the new wave of biosimilars

    One trial, the NOR-SWITCH study, has made a significant contribution to the evidence base for switching. ... Some policy makers have interpreted NOR-SWITCH results as confirmation of switching’s safety and efficacy.

  • Pfizer’s Remicade biosimilar receives Crohn's trial boost Pfizer’s Remicade biosimilar receives Crohn's trial boost

    In addition to existing data from the registration studies, real-world experience and the NOR-SWITCH trial, this data adds to the body of evidence supporting use of CT-P13 across ... That issue has already been studied to some extent in the NOR-SWITCH

  • NOR-SWITCH - the final piece in the biosimilar puzzle? NOR-SWITCH - the final piece in the biosimilar puzzle?

    that policymakers do not misinterpret or exaggerate the findings of the NOR-SWITCH trial. ... NOR-SWITCH is designed to evaluate the effects of a switch from the original biologic to a biosimilar.

  • Study finds no problems switching from Remicade to biosimilar Study finds no problems switching from Remicade to biosimilar

    The comparative trial - called NOR-SWITCH - was presented at the 2016 UEG Week in Vienna, Austria and showed that swapping from Remicade to a biosimilar version made by Celltrion posed no ... The data shows that safety and efficacy are maintained

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics